Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Investigating Free Cell Phones: What You Really want to Be aware01.01.1 - 2Becoming Familiar with an Unknown dialect: My Language Learning Excursion14.07.2023
- 3Earth’s magnetic field protects life on Earth from radiation, but it can move, and the magnetic poles can even flip07.12.2025
- 4Surveys of Thrillers That Re-imagined the Class01.01.1
- 5Craig the beer-ambassador elephant dies aged 5403.01.2026
- The most effective method to Pick the Right Material Organization: Your Definitive Aide
- King Charles shares cancer treatment update, says it's a 'personal blessing'
- This Flashy Old-School Design Trend From Italy Still Has A Place In Modern Kitchens
- Displaced Palestinian families suffer as heavy rains flood Gaza tent camps
- Addiction-stricken community struggles to keep a syringe program going after Trump's order
- Japan prepares to restart world's biggest nuclear plant, 15 years after Fukushima
- Kate Hudson, 46, says she doesn't need long workouts to feel good
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- National health ranking puts Georgia near bottom of list. Here's why
